Review: could Remicade cause Hepatosplenic T-cell Lymphoma?


Hepatosplenic t-cell lymphoma is found among people who take Remicade, especially for people who are male, 20-29 old , have been taking the drug for 2 - 5 years, also take medication Mercaptopurine, and have Crohn's disease . We study 119,767 people who have side effects while taking Remicade from FDA and social media. Among them, 297 have Hepatosplenic t-cell lymphoma. Find out below who they are, when they have Hepatosplenic t-cell lymphoma and more.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Remicade has active ingredients of infliximab. It is often used in crohn's disease. (latest outcomes from Remicade 120,130 users)

Hepatosplenic T-cell Lymphoma

Hepatosplenic t-cell lymphoma (neoplasm comprising medium-sized cytotoxic t-cells that show a significant sinusoidal infiltration in the liver, spleen, and bone marrow) has been reported by people with crohn's disease, ulcerative colitis, inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis (latest reports from 445 Hepatosplenic t-cell lymphoma patients).

On Oct, 18, 2016

119,767 people reported to have side effects when taking Remicade.
Among them, 297 people (0.25%) have Hepatosplenic T-cell Lymphoma

Number of reports submitted per year:

Could Remicade cause Hepatosplenic t-cell lymphoma?

Time on Remicade when people have Hepatosplenic T-cell Lymphoma *:

  • < 1 month: 20.59 %
  • 1 - 6 months: 27.94 %
  • 6 - 12 months: 4.41 %
  • 1 - 2 years: 1.47 %
  • 2 - 5 years: 42.65 %
  • 5 - 10 years: 1.47 %
  • 10+ years: 1.47 %

Gender of people who have Hepatosplenic T-cell Lymphoma when taking Remicade *:

  • female: 14.23 %
  • male: 85.77 %

Age of people who have Hepatosplenic T-cell Lymphoma when taking Remicade *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 24.89 %
  • 20-29: 34.39 %
  • 30-39: 25.79 %
  • 40-49: 1.36 %
  • 50-59: 9.05 %
  • 60+: 4.52 %

Top conditions involved for these people *:

  • Crohn's Disease (230 people, 77.44%)
  • Colitis Ulcerative (47 people, 15.82%)
  • Inflammatory Bowel Disease (14 people, 4.71%)
  • Diarrhoea (11 people, 3.70%)
  • Gastrooesophageal Reflux Disease (10 people, 3.37%)

Top co-used drugs for these people *:

  • Mercaptopurine (105 people, 35.35%)
  • Azathioprine (93 people, 31.31%)
  • Imuran (60 people, 20.20%)
  • Asacol (54 people, 18.18%)
  • Humira (44 people, 14.81%)

Top other side effects for these people *:

  • Drug Ineffective (32 people, 10.77%)
  • Thrombocytopenia (31 people, 10.44%)
  • Sepsis (31 people, 10.44%)
  • Leukopenia (31 people, 10.44%)
  • Pyrexia (28 people, 9.43%)

* Approximation only. Some reports may have incomplete information.

** Reports from social media are used.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you have Hepatosplenic t-cell lymphoma when taking Remicade?

Browse all side effects of Remicade

a b c d e f g h i j k l m n o p q r s t u v w x y z

Drugs that are associated with Hepatosplenic t-cell lymphoma

Hepatosplenic t-cell lymphoma

Could your condition cause Hepatosplenic t-cell lymphoma

Hepatosplenic t-cell lymphoma

Related studies

Can you answer these questions?

More questions for: Remicade, Hepatosplenic t-cell lymphoma

You may be interested in these reviews

More reviews for: Remicade, Hepatosplenic t-cell lymphoma

NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.